ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Does the ‘4% Rule’ Make Sense for Doctors?

The “4% rule” is nearly universal in the personal finance space. My goal here is to explain the 4% rule and its origins, while also

January 8, 2025

U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals

A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds with plans to alter payment methods for some hospitals that

September 17, 2024

Uncovering new antibiotics from the human gut microbiome

The average human gut contains roughly 100 trillion microbes, many of which are constantly competing for limited resources.

August 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.